SPRAVATO Treatment Center in Omaha, Nebraska
®
SPRAVATO® is the first prescription nasal spray, taken with an oral antidepressant, for:
-
Adults with treatment-resistant depression
in the SPRAVATO® clinical trials, treatment-resistant depression was diagnosed in adults who were struggling with major depressive disorder and had not responded adequately to at least two different antidepressants of adequate dose and duration in the current episode.
-
Depressive symptoms in adults with major depressive disorder with suicidal thoughts or actions
What is SPRAVATO ?
®
SPRAVATO® is an FDA-approved medication that is made from ketamine. Ketamine is a drug that has been found to be an extremely effective treatment for severe depression. Unlike other antidepressants, SPRAVATO® does not affect the serotonin levels in your brain. Instead, it helps to regulate your brain’s neuron activity in order to stimulate certain areas. This increased brain activity is thought to help reactivate the areas of the brain that have been affected by depression. This can help reduce or eliminate symptoms of depression.
While SPRAVATO® treatment centers may be one of the newest options in addiction treatment, many studies have shown that ketamine is effective in reducing depression symptoms, including thoughts of self-harm. Perhaps one of the most appealing reasons to try SPRAVATO® is that, unlike traditional antidepressants that can take weeks or months to show results, ketamine can reduce your symptoms in as little as 24 hours after treatment begins.
What to expect from a SPRAVATO Treatment Center
®
If you and your provider have decided that SPRAVATO® is the best way to treat your TRD, you will schedule a follow-up appointment to take the medication at your SSPRAVATO® treatment center. This is because SPRAVATO® is not a daily pill like traditional antidepressants. Instead, it is a nasal spray for depression that must be prescribed and taken by the client at an approved SPRAVATO® treatment center. Clients will administer the nasal spray themselves. In addition, they will be monitored by the medical staff for one to two hours. If you experience any rare but serious side effects, you will receive immediate medical care.
Most clients will benefit the most from having twice-weekly doses of SPRAVATO® for the first month of their treatment schedule. Following this period, you will be reduced to just one dose per week. This most often continues for at least another two months. Most clients find that a total of three months of treatment is enough to give them relief from their symptoms. Others may need to continue treatment for longer in order to find the level of relief necessary for them.
Spravato Providers
Marisha VanVleet - VCH
APRN-CNP PMHNP-BC
R. Dawn Slominski
DNP, APRN
John Ramsey
MSN, APRN, PMHNP-BC
Troyia Anderson
DNP, APRN-RN, PMHNP-BC
Margaret Chipendo
MSN, APRN, FNP/PMHNP-BC
Kristi Bose
PMHNP-BC, Co-Founder, Director of Clinical Operations
Marisha VanVleet - SSP
APRN-CNP PMHNP-BC
Jackie Wayman
APRN, PMHNP-BC
Mary Dishman
APRN, PMHNP-BC
Holly Montgomery
MSN, APRN, PMHNP-BC
Julie Zulkosky
DNP, APRN, PMHNP-BC, Co-Founder
Melissa Smith
DNP, APRN-NP, PMHNP-BC
Rojay Passley
MSN, APRN, PMHNP-BC